Clinical Trials

Title

A Phase 2/3 Randomized Double-Blind Placebo-controlled study to evaluate the safety and efficacy of DM199 for the treatment of Acute Ischemic Stroke. Enrolling

• Short Title DM199-2021-001
• Category Neurology
• Status Recruiting

Diagnosis

Acute Ischemic Stroke

Participating Locations

Erlanger

Principal Investigator

Mounzer Yassin-Kassab, MD

Contact

• Name Erlanger Institute for Clinical Research
• Phone 4237783900
• Email [email protected]

Description

This trial is for adults, 18 and older, who have experienced an Acute Ischemic Stroke within the last 24 hours. They must not qualify for standard of care therapy. Patient must also stop any ACEi therapy 24 hours prior to first treatment, or switch to another antihypertensive pharmacological treatment. This study is a randomized study, meaning you nor the clinical trial team will know what drug you are getting. Treatment duration is 21 days plus 90 days of follow up. It is an IV infusion that is administered at the hospital; then, injections to be administered twice a week for 21 days at home or rehab facility.